身痛逐瘀汤加减治疗中轴型强直性脊柱炎的临床观察

Observation on treating axia-ankylosing spondylitis with the Shentong Zhuyu decoction

目的:探讨身痛逐瘀汤加减治疗中轴型强直性脊柱炎(Axia-ankylosing Spondylitis,AS)的疗效。方法:将28例AS患者根据随机数字法分为两组,每组14例。对照组采用沙利度胺,观察组采用身痛逐瘀汤加减,疗程为3个月。统计两组的炎性指标、AS功能指数量表评分(The Bath Ankylosing Spondylitis Functional Index,BASFI)、AS疾病活动指数量表评分(Bath Ankylosing Spondylitis Disease Activity Index,BASDAI)、疼痛评分(Visual Analogue Score,VAS)及评价中轴型强直性脊柱炎活动范围或脊柱活动度的AS衡量指数评分(Bath Ankylosing Spondylitis Metrology Index,BASMI)。结果:治疗后,两组超敏C反应蛋白(high sensitivity C-reactive Protein,hs-CRP)、VAS、BASFI、BASDAI评分均较治疗前降低,差异有统计学意义(P <0.05),观察组与对照组无明显差异(P> 0.05)。结论:身痛逐瘀汤加减与沙利度胺都可以提高AS患者的治疗效果,同时身痛逐瘀汤加减能改善疾病状况,疗效显著且安全性高,值得推广。

Objective: To explore clinical efficacy of the Shentong Zhuyu decoction( 身痛逐瘀汤) on axia-ankylosing spondylitis. Methods: 28 cases were randomly divided into two groups, 14 cases in each group. Patients in the control group were treated with thalidomide;the study group was treated with the Shentong Zhuyu decoction, for 3 months. The clinical efficacy, inflammatory indicators, BASFI, BASDAI, VAS and BASMI in groups were calculated. Results: After treatment, the scores of hs-CRP, VAS, BASFI and BASDAI in two groups were lower than those before treatment, with significantly statistical differences in groups(P<0.05);there was no significantly difference between the study group and the control group(P>0.05). Conclusion: The Shentong Zhuyu decoction was effective on AS, as same as the thalidomide;it could improve the function of the body, with good efficacy and high safety, is worthy of promoting.